Ratings Supermax Corporation

Equities

SUPERMX

MYL7106OO007

End-of-day quote BURSA MALAYSIA Other stock markets 06:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
1.01 ^MYR	-6.48%		+16.09%	+7.45%

May. 10	Supermax Buys Out Supermax Healthcare Canada for C$5.5 Million	MT
May. 09	Supermax Corporation Berhad entered into a Share Sale Agreement to acquire remaining 33% stake in Supermax Healthcare Canada Inc. from Sylvain Bergeron for CAD 5.5 million.	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company appears to be poorly valued given its net asset value.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company sustains low margins.
With an expected P/E ratio at 101 and 33.67 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SUPERMAX CORPORATION	+7.45%	553M		C+
COLOPLAST A/S	+8.94%	27.55B		B+
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-31.54%	3.13B		B-
HARTALEGA HOLDINGS	+35.19%	2.66B		B
WINNER MEDICAL CO., LTD.	-19.19%	2.43B		C+
INTCO MEDICAL TECHNOLOGY CO., LTD.	+8.09%	2.27B	-	A-
TOP GLOVE CORPORATION BHD.	+33.33%	2.05B		B
HARBIN FUERJIA TECHNOLOGY CO., LTD.	-1.73%	2.08B		-
KOSSAN RUBBER INDUSTRIES	+34.05%	1.35B		C
NAKANISHI INC.	+3.16%	1.34B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes